精品无吗Av一区二区_日韩亚洲中文无码_国产免费久久精品44_看全色黄大色黄大片不卡

<dfn id="l183i"><cite id="l183i"><kbd id="l183i"></kbd></cite></dfn>

<dfn id="l183i"></dfn>

<dfn id="l183i"><cite id="l183i"></cite></dfn>

<center id="l183i"><ol id="l183i"></ol></center>

Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)

2024-10-31
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY?)

2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School

2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates

2023-12-19
Beihai Biotech Secures “Drug Manufacturing Certificate”

2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023

2023-06-12
貝海生物用于治療晚期三陰性乳腺癌的創(chuàng)新藥物BH009獲批開展II期臨床試驗

2023-04-10
貝海生物BH009新藥項目在晚期頭頸部鱗癌和卵巢癌患者中的I期臨床試驗完成首例患者給藥

2023-03-09

Contact Information

Company address：Blg 2, No. 6366, Zhuhai Ave., Jinwan, Zhuhai, 519090, China
Tel：0756-6349669
Human resources contact：hr@bayhibiotech.com
Business cooperation contact：hjiang@bayhibiotech.com

: Wechat Official Account

<u id="6xuxp"><pre id="6xuxp"><strong id="6xuxp"></strong></pre></u><menuitem id="6xuxp"></menuitem>